公开(公告)号：USRE49735E1

公开(公告)日：2023-11-28

申请号：US17481947

申请日：2021-09-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Andrew P. Degnan ,  Hong Huang ,  Lawrence B. Snyder ,  Fukang Yang ,  Kevin W. Gillman ,  Michael Frederick Parker

IPC: C07D413/04 ,  C07D263/18 ,  C07D413/10 ,  C07D413/14

CPC classification number: C07D413/04 ,  C07D263/18 ,  C07D413/10 ,  C07D413/14

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20230322803A1

公开(公告)日：2023-10-12

申请号：US17913206

申请日：2021-03-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Andrew P. Degnan ,  Godwin Kwame Kumi ,  Andrew J. Tebben ,  Audris Huang ,  Peter Kinam Park ,  Donna M. Bilder ,  Emily Charlotte Cherney ,  Ashok Vinayak Purandare

IPC: C07D498/04 ,  C07D471/04 ,  C07D401/14

CPC classification number: C07D498/04 ,  C07D401/14 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US11548870B2

公开(公告)日：2023-01-10

申请号：US16950978

申请日：2020-11-18

Applicant: Bristol-Myers Squibb Company

Inventor： Andrew P. Degnan ,  Godwin Kwame Kumi ,  Audris Huang ,  James Aaron Balog ,  Ashok Vinayak Purandare ,  Weifang Shan ,  Guo Li

IPC: C07D407/14 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04 ,  C07D491/107 ,  A61K31/4439 ,  A61P35/00 ,  C07D405/14 ,  C07D498/18

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: Z is CR6R6 or C═O; Ring A is: and R1, R2, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

公开(公告)号：US10174024B2

公开(公告)日：2019-01-08

申请号：US15573151

申请日：2016-05-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Wen-Ching Han ,  Andrew P. Degnan ,  Jeffrey A. Deskus ,  Ashvinikumar V. Gavai ,  Patrice Gill ,  William D. Schmitz ,  John E. Starrett, Jr.

IPC: C07D471/04

Abstract: The present invention is directed to tricyclic compounds of formula (I), pharmaceutically acceptable compositions comprising compounds of the invention and said compositions for use in methods for the treatment of various disorders in particular cancer.

公开(公告)号：US20180030057A1

公开(公告)日：2018-02-01

申请号：US15641908

申请日：2017-09-21

Applicant: Bristol-Myers Squibb Company

Inventor： Andrew P. Degnan

IPC: C07D487/04

CPC classification number: C07D487/04

Abstract: The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which arc CGRP-receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).

公开(公告)号：US09688669B2

公开(公告)日：2017-06-27

申请号：US15026759

申请日：2014-10-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Andrew P. Degnan ,  Darrell Maxwell ,  Matthew D. Hill ,  Haiquan Fang ,  Michael F. Parker ,  Fukang Yang ,  Joanne J. Bronson ,  John E. Macor

IPC: C07D413/14 ,  C07D413/04 ,  C07D263/24

CPC classification number: C07D413/04 ,  C07B2200/07 ,  C07D263/24 ,  C07D413/14

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.

公开(公告)号：US20160237072A1

公开(公告)日：2016-08-18

申请号：US15026759

申请日：2014-10-06

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Andrew P. Degnan ,  Darrell Maxwell ,  Matthew D. Hill ,  Haiquan Fang ,  Michael F. Parker ,  Fukang Yang ,  Joanne J. Bronson ,  John E. Macor

IPC: C07D413/04 ,  C07D263/24 ,  C07D413/14

CPC classification number: C07D413/04 ,  C07B2200/07 ,  C07D263/24 ,  C07D413/14

Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.

Abstract translation: 本公开内容通常涉及式I化合物，包括其盐，以及使用该化合物的组合物和方法。 这些化合物是mGluR5受体的配体，激动剂和部分激动剂，并且可用于治疗中枢神经系统的各种疾病。